- Home IMPART
- CHSRF - CIHR Chair
- Drug Policy Residency
- Faculty and Staff
- Health Outcomes Fellowship
- IMPART Seminar Series
- Workshops and Symposiums
- Contact Us
Dr. Ingrid S. Sketris
Dr. Sketris is a Professor of the College of Pharmacy, School of Nursing, School of Health Services Administration, Faculty of Computer Science, and the Department of Community Health and Epidemiology, Dalhousie University. She is a graduate of the University of Toronto (BSc(Phm), 1977), University of Minnesota (PharmD, 1979), University of Tennessee, Centre for Health Sciences (Residency in Clinical Toxicology/Pharmacy Practice, 1980) and Dalhousie University (MPA(HSA) 1989). Dr. Sketris was a member of the Scientific Advisory Panel of the Canadian Coordinating Office for Health Technology Assessment from 1996 to1998 and of the Patented Medicine Prices Review Board from 1999 to 2004. She is currently a member of the CIHR Institute Advisory Board for Health Services and Policy Research. In June 2000, Dr. Sketris received a Chair in health services research focusing on pharmaceutical policy and utilization management from the Canadian Health Services Research Foundation (CHSRF) and the Canadian Institutes of Health Research (CIHR) cosponsored by the Nova Scotia Health Research Foundation. She and her colleagues at IMPART
conduct research related to medication management. Dr. Ingrid Sketris received the Anne and Neil McArthur Award April 25, 2006. This award is presented annually to a researcher who works in the area of study covered by the Father Sean O’Sullivan Research Centre affiliated with McMaster University and is an award to honor the achievements of an outstanding researcher. In 2007, she received the Canadian Pharmacists’ Association Centennial Award. This award recognizes 100 leaders and builders of the Canadian Pharmacists Association and the profession of pharmacy in Canada over the past 100 years. In 2007, Dr. Ingrid Sketris received the Women of Excellence Award for Education and Research. This award is presented by the Canadian Progress Club – Halifax-Cornwallis. She was on the Management Committee of the Dalhousie Baltic Economic program to train civil servants
1. Groves KEM, MacKinnon NJ, Sketris IS. Prescribing Behavior. In: Social and Behavioral Aspects of Pharmaceutical Care, 2nd Edition. Rickles NM, Wertheimer AI, Smith MC, eds. Jones and Bartlett Publishers. Sudbury, MA; 2009: 141-76.
2. Sketris IS, Langille Ingram E, Lummis H. 2007. Optimal Prescribing and Medication Use in Canada. Challenges and Opportunities. Background report prepared for Health Council of Canada Symposium, Safe and Sound – Optimizing Prescribing Behaviours. Montreal, June 12-13. www.healthcouncilcanada.ca.
3. Graham S, Frail DM, Allen M, Sketris IS. 2007. The Dalhousie Academic Detailing Service: Designing an Intervention on the Topic of Osteoarthritis. In: MacKinnon NJ, editor. Safe and Effective. The Eight Essential Elements of an Optimal Medication-Use System. Ottawa: Canadian Pharmacists Association; 187-199. ISBN 978-1-894402-31-6.
4. Metge M, Sketris IS. Pharmaceutical Policy. 2007. In: MacKinnon NJ, editor. Safe and Effective. The Eight Essential Elements of an Optimal Medication-Use System. Ottawa: Canadian Pharmacists Association; 117-158. ISBN 978-1-894402-31-6.
5. Barozzi N, Sketris I, Cooke C, Tett S. 2009. Comparison on Non-steroidal Anti-inflammatory Drugs and Cyclo-Oxygenase-2 (COX-2) Inhibitors Use in Australia and Nova Scotia (Canada). British Journal of Clinical Pharmacology; 68:1; 106-115. doi: 10.1111/1365-2125.2009.03410.x.
6. Kent A. Sketris I, Johnston BL, Sommers RB. 2009. Effect of Utilization Policies for Fluoroquinolones: A Pilot Study in Nova Scotia Hospitals. Can J Hosp Pharm 62(1):12-20.
7. Sketris IS, Langille Ingram EM, Lummis HL. 2009. Strategic opportunties for effective optimal prescribing and medication management. Can J Clin Pharmacol; 16(1):e103-25.
8. Sketris I. 2009. Extending Prescribing Privileges in Canada. CPJ; 142(1):17-19.
9. Sargeant J, Hurley KF, Duffy J, Sketris I, Sinclair D, Ducharme J. 2008. Lost in translation or just lost? Ann Emerg Med; 52(5):575-6.
10. Lowe DO, Lummis H, Zhang Y, Sketris IS. 2008. Effect of Educational and Policy Interventions on Institutional Utilization of Wet Nebulization Respiratory Drugs and Portable Inhalers. Can J Clin Pharmacol 15(2):e334-e343.
11. Graham SD, Hartzema AG, Sketris IS, Winterstein A. 2008. Effect of an Academic Detailing Intervention on the Utilization Rate of Cyclooxygenase-2 Inhibitors in the Elderly. The Annals of Pharmacotherapy; 42:749-756. DOI 10.1345/aph.1K537.
12. Lummis H, Sketris IS, Gubitz GJ, Joffres MR, Flowerdew GJ. 2008. Medication Persistence Rates and Factors Associated with Persistence in Patients Following Stroke: A Cohort Study. BMC Neurology, 8:25. DOI:10.1186/1471-2377-8-24.
13. Lummis H, Sketris IS. Use of Patients’ Own Medications in Canadian Hospitals: A National Survey. 2008. Can J Hosp Pharm; 61(2):114-122.
14. Smith AJ, Sketris IS, Cooke C, Gardner D, Kisely S, Tett SE. 2008. A Comparison of Benzodiazepine and Related Drug Use in Nova Scotia, Canada and Australia. The Canadian Journal of Psychiatry; 53(8):545-552.
15. Smith AJ, Sketris IS, Cooke C, Gardner D, Kisely S, Tett SE. 2008. A Comparison of Antidepressant Use in Nova Scotia, Canada and Australia. Pharmacoepidemiology and Drug Safety; 17:697-706. DOI: 10.1002/pds.1541.
16. Sanyal C, Graham SD, Cooke C, Sketris IS, Frail DM, Flowerdew G. 2008. The relationship between type of drug therapy and blood glucose self-monitoring test strips by beneficiaries of the Seniors’ Pharmacare Program in Nova Scotia, Canada. BMC Health Services Research; 8:11. DOI:10.1186/147206963-8-111.
17. Hurley KF, Sargeant J, Duffy J, Sketris IS, Sinclair D, Ducharme J. 2008. Perceptual Reasons for Resistance to Change in the Emergency Department Use of Holding Chambers for Children with Asthma. Annals of Emergency Med; 51: 70-77. doi:10.1016/j.annemergmed.2007.04.008.
18. Cox J, Johnstone D, Nemis-White J, Montague T; ICONS Investigators. 2003. Optimizing healthcare at the population level: results of the improving cardiovascular outcomes in Nova Scotia partnership. Healthcare Quarterly; 11(2):28-41.
19. Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS. 2008. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology. Aug 19;71(8):615 (author reply).
20. Gaikwad R, Sketris IS, Shepherd M, Duffy. 2007. Evaluation of accuracy of drug interaction alerts triggered by two electronic medical record systems in primary healthcare. Health Informatics J; 13(3):163-177. doi:10.1177/1460458207079836.
21. Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS. 2007. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, 69(15):1498-1507.
22. Sketris IS. 2007. Analyzing International Prescribing Patterns and Medication Use: An Approach to Assisting in the Improvement of Health Care Quality and Patient Outcomes. Clinical Therapeutics; 29(5):936-938.
23. Kephart G, Skedgel C, Sketris IS, Grootendorst P, Hoar J. 2007. Effect of Copayments on Drug Use in the Presence of Annual Payment Limits. Am J Managed Care; 13(part 2):328-334.
24. Allen M, Sketris IS, Langille Ingram E, Farrell L. 2007. Maritime Provinces Symposium on Health Technology Assessment. Journal of Continuing Education in the Health Professions, 27(1):60-61.
25. Bowles SK, Sketris IS, Kephart G. 2007. Use of Wet-Nebulized Inhaled Respiratory Medications Under Criteria-Based Reimbursement Guidelines in a Publicly-Funded Seniors’ Pharmacare Program. American Journal of Geriatric Pharmacotherapy; doi.10.1016/j.ajopharm.2007.05.003